Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced upcoming presentations at two major healthcare investment conferences.

The company will participate in the Cantor Fitzgerald 2025 Annual Global Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. Both events will be held in New York and feature presentations from key executives including CEO Alex Sapir, CFO Alan Musso, and SVP of Early Development Iain Fraser.

One-on-one meetings with management will be available to interested investors through conference representatives.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of inducement stock options to new employees. The company issued an aggregate of 36,400 stock options with an exercise price of $6.96 per share, matching the closing price on August 4, 2025.

The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term and follow a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.

Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 2025 financial results and clinical progress. The company announced promising results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease, showing an 8.6% mean increase in fetal hemoglobin and 67% F-cells, with no serious adverse events.

Financial highlights include $214.1 million in cash reserves as of June 30, 2025, extending runway into 2028. Q2 2025 resulted in a net loss of $17.3 million, compared to net income of $55.4 million in Q2 2024. R&D expenses decreased to $13.0 million from $17.3 million year-over-year, while G&A expenses reduced to $6.8 million from $10.2 million.

Fulcrum Therapeutics (NASDAQ:FULC) announced positive results from the 12 mg dose cohort of Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD). The trial demonstrated a significant 8.6% absolute mean increase in fetal hemoglobin (HbF) after 12 weeks of treatment, with 7 of 16 patients achieving HbF levels above 20%.

Key findings include pan-cellular HbF induction with F-cells increasing from 34% to 67%, meaningful improvements in hemolysis markers, and a 0.9 g/dL increase in total hemoglobin. The drug showed encouraging trends in reducing vaso-occlusive crises (VOCs) and maintained a favorable safety profile with no treatment-related serious adverse events.

The study involved 135 adults across multiple cohorts, including 103 healthy subjects and 32 SCD patients, with all treatment-related adverse events being Grade 1.

Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for July 29, 2025, at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.

The presentation will feature distinguished speakers including Dr. Sheinei Alan from the Inova Fairfax Adult Sickle Cell Program and Dr. Wally Smith from the VCU Adult Sickle Cell Program, who will join Fulcrum's management team to discuss the findings.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company awarded 130,000 options at an exercise price of $7.02 per share, matching the closing price on July 7, 2025.

The options, granted under Fulcrum's 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.

Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company, announced the granting of non-statutory stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The company granted 70,000 stock options at an exercise price of $6.96 per share, matching the closing price on June 2, 2025. The options have a ten-year term and follow a four-year vesting schedule: 25% vests after the first year, followed by quarterly vesting of 6.25% over the next three years, contingent on continued employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Fulcrum Therapeutics (NASDAQ: FULC) announced upcoming presentations at two major medical conferences: the 5th Global Congress on Sickle Cell Disease in Abuja, Nigeria (June 3-6, 2025) and the 2025 European Hematology Association Congress in Milan, Italy (June 12-15, 2025).

The company will present four posters focusing on Pociredir, their novel oral treatment for Sickle Cell Disease (SCD). The presentations will cover preclinical and early clinical results, Phase 1b trial design, pharmacokinetics and pharmacodynamics in healthy adults, and the drug's mechanism as an EED inhibitor for fetal hemoglobin induction.

Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 8:00 am ET in Miami, FL. The presentation will be available via webcast on the company's investor relations website, with replay access for at least 30 days following the event.